Stephen D. Rosasco

Array ( [id] => 18988166 [patent_doc_number] => 20240060135 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-22 [patent_title] => THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER [patent_app_type] => utility [patent_app_number] => 17/937102 [patent_app_country] => US [patent_app_date] => 2022-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 132800 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17937102 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18198470 [patent_doc_number] => 20230051989 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-16 [patent_title] => CHIMERIC ANTIGEN RECEPTOR AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/932259 [patent_app_country] => US [patent_app_date] => 2022-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24290 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17932259 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18256417 [patent_doc_number] => 20230083456 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-16 [patent_title] => COMPOSITIONS AND METHODS FOR DIAGNOSING COLORECTAL CANCER [patent_app_type] => utility [patent_app_number] => 17/930460 [patent_app_country] => US [patent_app_date] => 2022-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13658 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17930460 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19426162 [patent_doc_number] => 12085569 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-10 [patent_title] => Plasma autoantibody biomarkers for basal like breast cancer [patent_app_type] => utility [patent_app_number] => 17/940883 [patent_app_country] => US [patent_app_date] => 2022-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 2259 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17940883 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18421597 [patent_doc_number] => 20230176061 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => METHODS FOR DIAGNOSING HIGH-RISK CANCER USING POLYSIALIC ACID AND ONE OR MORE TISSUE-SPECIFIC BIOMARKERS [patent_app_type] => utility [patent_app_number] => 17/884465 [patent_app_country] => US [patent_app_date] => 2022-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25546 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17884465 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18666282 [patent_doc_number] => 11773160 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2023-10-03 [patent_title] => Immune-stimulating IL-2 fusion proteins [patent_app_type] => utility [patent_app_number] => 17/817886 [patent_app_country] => US [patent_app_date] => 2022-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 24684 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 128 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17817886 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18737950 [patent_doc_number] => 20230346852 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-02 [patent_title] => APPLICATION OF BACTERIA IN PREPARATION OF SYNERGIST FOR IMMUNE CHECKPOINT INHIBITOR [patent_app_type] => utility [patent_app_number] => 18/025640 [patent_app_country] => US [patent_app_date] => 2022-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13692 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18025640 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18077433 [patent_doc_number] => 20220403045 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-22 [patent_title] => RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS [patent_app_type] => utility [patent_app_number] => 17/848694 [patent_app_country] => US [patent_app_date] => 2022-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26648 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17848694 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18110853 [patent_doc_number] => 20230003733 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-05 [patent_title] => BIOMARKERS AND USES THEREOF FOR SELECTING IMMUNOTHERAPY INTERVENTION [patent_app_type] => utility [patent_app_number] => 17/846966 [patent_app_country] => US [patent_app_date] => 2022-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26408 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17846966 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18167865 [patent_doc_number] => 20230034473 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-02 [patent_title] => METHODS OF TREATING FIBROBLAST GROWTH FACTOR 19-MEDIATED CANCERS AND TUMORS [patent_app_type] => utility [patent_app_number] => 17/843852 [patent_app_country] => US [patent_app_date] => 2022-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25169 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17843852 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18223630 [patent_doc_number] => 20230062624 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-02 [patent_title] => CD3/CD38 T CELL RETARGETING HETERO-DIMERIC IMMUNOGLOBULINS AND METHODS OF THEIR PRODUCTION [patent_app_type] => utility [patent_app_number] => 17/806218 [patent_app_country] => US [patent_app_date] => 2022-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27379 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17806218 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18268498 [patent_doc_number] => 20230089740 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-23 [patent_title] => CANCER TREATMENT [patent_app_type] => utility [patent_app_number] => 17/805336 [patent_app_country] => US [patent_app_date] => 2022-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15526 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17805336 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18058433 [patent_doc_number] => 20220389519 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-08 [patent_title] => BIOMARKERS PREDICTIVE OF ANTI-IMMUNE CHECKPOINT RESPONSE [patent_app_type] => utility [patent_app_number] => 17/826477 [patent_app_country] => US [patent_app_date] => 2022-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 73076 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17826477 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17865417 [patent_doc_number] => 20220288152 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => WEEKLY DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATES [patent_app_type] => utility [patent_app_number] => 17/752519 [patent_app_country] => US [patent_app_date] => 2022-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12688 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17752519 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19201493 [patent_doc_number] => 20240173392 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-30 [patent_title] => USE OF THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF PATIENTS WITH TUMORS OF EPITHELIAL ORIGIN [patent_app_type] => utility [patent_app_number] => 17/789888 [patent_app_country] => US [patent_app_date] => 2022-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3986 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17789888 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18093187 [patent_doc_number] => 20220411528 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => METHODS FOR TREATMENT OF CD20-POSITIVE PROLIFERATIVE DISORDER WITH MOSUNETUZUMAB AND POLATUZUMAB VEDOTIN [patent_app_type] => utility [patent_app_number] => 17/744262 [patent_app_country] => US [patent_app_date] => 2022-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39357 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17744262 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19368351 [patent_doc_number] => 12060423 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-08-13 [patent_title] => Humanized, mouse or chimeric anti-CD47 monoclonal antibodies [patent_app_type] => utility [patent_app_number] => 17/739308 [patent_app_country] => US [patent_app_date] => 2022-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 38 [patent_no_of_words] => 30013 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 204 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17739308 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19763193 [patent_doc_number] => 12221466 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-11 [patent_title] => TCR, polypeptide, expression vector, host cell, pharmaceutical composition and method for obtaining TCR [patent_app_type] => utility [patent_app_number] => 17/739317 [patent_app_country] => US [patent_app_date] => 2022-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 16 [patent_no_of_words] => 8448 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17739317 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18077437 [patent_doc_number] => 20220403049 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-22 [patent_title] => HETERODIMERIC ANTIBODIES THAT BIND CD3 AND CD38 [patent_app_type] => utility [patent_app_number] => 17/736475 [patent_app_country] => US [patent_app_date] => 2022-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22251 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17736475 [rel_patent_id] =>[rel_patent_doc_number] =>)